Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128589 | 1.00 | CYP3A4 (0.48) | CYP3A4ALOX5APFEN1MAP3K11LRRK2 | |
| SCHEMBL2128248 | 0.88 | CYP3A4 (0.54) | CYP3A4 | |
| SCHEMBL1543373 | 0.85 | CYP3A4 (0.59) | CYP3A4TDO2 | |
| SCHEMBL2129430 | 0.85 | CYP3A4 (0.59) | CYP3A4TDO2 | |
| SCHEMBL1543597 | 0.85 | CYP3A4 (0.65) | CYP3A4ALOX5APFEN1MAP3K11LRRK2 | |
| SCHEMBL1543595 | 0.85 | CYP3A4 (0.65) | CYP3A4ALOX5APFEN1MAP3K11LRRK2 | |
| SCHEMBL1543370 | 0.85 | CYP3A4 (0.43) | CYP3A4ALOX5APFEN1 | |
| SCHEMBL1543365 | 0.85 | CYP3A4 (0.43) | CYP3A4ALOX5APFEN1 | |
| SCHEMBL2128932 | 0.85 | CYP3A4 (0.43) | CYP3A4ALOX5APFEN1 | |
| SCHEMBL2128238 | 0.83 | CYP3A4 (0.51) | CYP3A4MAP3K11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | claimed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | CYP3A4 528/4885ALOX5AP 3584/4885FEN1 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.